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Abstract
BCL2 family proteins including pro-survival proteins, BH3-only proteins and BAX/BAK pro-
teins control mitochondria-mediated apoptosis to maintain cell homeostasis via the removal
of damaged cells and pathogen-infected cells. In this study, we examined the roles of BCL2
proteins in the induction of apoptosis in cells upon infection with flaviviruses, such as Japa-
nese encephalitis virus, Dengue virus and Zika virus. We showed that survival of the
infected cells depends on BCLXL, a pro-survival BCL2 protein due to suppression of the
expression of another pro-survival protein, MCL1. Treatment with BCLXL inhibitors, as well
as deficient BCLXL gene expression, induced BAX/BAK-dependent apoptosis upon infec-
tion with flaviviruses. Flavivirus infection attenuates cellular protein synthesis, which confers
reduction of short-half-life proteins like MCL1. Inhibition of BCLXL increased phagocytosis of
virus-infected cells by macrophages, thereby suppressing viral dissemination and chemo-
kine production. Furthermore, we examined the roles of BCLXL in the death of JEV-infected
cells during in vivo infection. Haploinsufficiency of the BCLXL gene, as well as administration
of BH3 mimetic compounds, increased survival rate after challenge of JEV infection and
suppressed inflammation. These results suggest that BCLXL plays a crucial role in the sur-
vival of cells infected with flaviviruses, and that BCLXL may provide a novel antiviral target to
suppress propagation of the family of Flaviviridae viruses.
Author summary
The genus Flavivirus including Japanese encephalitis virus, Dengue virus, and Zika virus
all of which are mosquito-borne human pathogen and cause serious diseases in humans.
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Therefore, the development of effective vaccines and antivirals against several flaviviruses
is still needed. BCL2 family proteins control mitochondria-mediated apoptosis to main-
tain cell homeostasis via the removal of damaged cells and pathogen-infected cells, dereg-
ulation of which leads to severe diseases including cancer and autoimmune diseases.
Here, we showed that BCLXL is a critical cell survival factor during infection with flavivi-
ruses, and that inhibition of BCLXL by treatment with BH3 mimetics restricts the
production of infectious particles and the expression of chemokines in vitro and in vivo.
Inhibition of BCLXL induces apoptosis in cells infected with flaviviruses and these cells
are quickly removed by engulfment of phagocytes, which leads to inhibition of virus dis-
semination without any inflammatory reaction. Based on these data, BCLXL would appear
to be a suitable target for the development of novel antivirals against a broad range of fla-
vivirus infections.
Introduction
The genus Flavivirus belongs to the family Flaviviridae and includes the Japanese encephalitis
virus (JEV), Dengue virus (DENV), West Nile virus (WNV) and Zika virus (ZIKV), all of
which are mosquito-borne human pathogens [1,2]. The flaviviruses are internalized into den-
dritic cells, such as Langerhans cells [3], and keratinocytes in skin [4] through mosquito bites.
Dendritic cells that are thus infected with flaviviruses are activated and migrate into the lymph
nodes, facilitating viral spread into peripheral tissues [5] and the induction of visceral and/or
central nervous system diseases. DENV infection may generate dengue haemorrhagic fever
and dengue shock syndrome [6], while infection with either WNV or JEV can cause severe
encephalitis [7,8]. Recently, an outbreak of ZIKV infection in Brazil was linked to birth defects,
including microcephaly, and to Guillain-Barre syndrome in adults [9,10]. Therefore, the devel-
opment of effective vaccines and antiviral drugs against the family of flaviviruses is an urgent
need.
Infection with flaviviruses induces apoptosis in cells by the production of reactive oxidative
species, unfolded protein responses, and viral proteins [11], in addition to other types of cell
death, such as necrosis and pyroptosis. Receptor-interacting serine/threonine-protein kinase-3
(RIPK3), a central player of necroptosis, has been shown to play an additional role during
virus infection [12]. Infection with either DENV or hepatitis C virus (HCV) induces interleu-
kin-1β production and pyroptosis [13]. The biological significance of pyroptosis in the patho-
genicity of flavivirus infection remains largely unknown [14].
Apoptosis is a type of programmed cell death that removes excess cells during development,
as well as during routine homeostasis [15–17]. B-cell lymphoma-2 (BCL2) family proteins
play central roles in mitochondria-mediated apoptosis [18]. BCL2 family proteins have been
divided into three groups: BH3-only proteins, BAX/BAK proteins and pro-survival proteins.
Once an apoptotic stimulus such as DNA damage occurs, BH3-only proteins, such as BIM,
BID, PUMA, BAD and NOXA, are activated and directly or indirectly activate BAX and BAK.
Activated BAX/BAK forms homo-oligomers that permeabilize mitochondria and allow the
release of pro-apoptotic factors such as cytochrome c, which promotes activation of caspases
[19]. Pro-survival proteins, such as BCL2, BCLW, BCLXL, MCL1 and A1, sequester BH3-only
proteins to prevent self-activation of BAX/BAK by interaction with the BH3 domains of BAX/
BAK [20]. In a notable extension to cancer therapy, small molecule inhibitors have been devel-
oped, including ABT-737, ABT-263 (navitoclax, an orally available clinical derivative of ABT-
737), ABT-199 (venetoclax) and A-1331852. ABT-199 and A-1331852 target BCL2 and
BCLXL-dependent cell survival upon infection with flaviviruses
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BCLXL, respectively, while ABT-737 and ABT-263 target BCL2, BCLXL and BCLW. ABT-199
was approved by the United States Food and Drug Administration for the treatment of 17-p
deleted chronic lymphocytic leukaemia (CLL) [21], supporting the therapeutic use of induc-
tion of cell death by mitochondria-mediated apoptosis to eliminate unnecessary cells.
In this study, we showed that cells infected with flaviviruses including JEV, DENV and
ZIKV specifically induced apoptosis by inhibition of BCLXL through the suppression of MCL1
expression. Furthermore, we showed that host protein synthesis is impaired in cells upon
infection with flaviviruses, leading to the decay of labile proteins such as MCL1. Treatment
with inhibitors for BCLXL, as well as deficiency of BCLXL gene, induced BAX/BAK-dependent
apoptosis in the infected cells. Finally, engulfment of virus-infected cells by macrophages was
significantly enhanced by the inhibition of BCLXL without an increase of the production of
pro-inflammatory cytokines, which led to the suppression of viral dissemination.
Results
Inhibition of BCLXL accelerates cell death upon infection with flaviviruses
Firstly, to examine the roles of BAX/BAK-dependent apoptosis during flavivirus-infected cells,
we generated BAX and BAK double-knockout (BAX/BAKDKO) Huh7 cell lines (clones #29
and #47) and infected with Japanese encephalitis virus (JEV) (S1A Fig). Although Huh7 cells
induced cell death at 4 days post-infection with JEV, BAX/BAKDKO cells exhibited a complete
resistant to mitochondria mediated apoptosis [22], suggesting that cells infected with JEV
induce mitochondria-mediated apoptosis at 4 days post-infection. However, BAX/BAKDKO
cells also exhibited cell death at 5 and 6 days post-infection. The BAX/BAK-independent cell
death might be induced by necrosis or pyroptosis rather than apoptosis as previously reported
(Fig 1A) [12].
Recent clinical studies showed that survival of chronic lymphocytic leukaemia (CLL) is
largely dependent on BCL2 [21], and that loss of a single Bclx allele attenuates MYC-induced
lymphoma in vivo [23]. In addition, selective inhibition of MCL1 has been shown to induce
apoptosis in acute myelogenous leukaemia cell lines without signs of toxicity to normal human
haematopoietic progenitor cells [24]. It had been reported that cellular stress such as ER stress,
DNA damage and innate immune response affects on the expression of BCL2 protein family
[25–27]. Therefore, we speculated that virus infection alters the expression of BCL2 proteins
through the induction of cellular stress. BH3-only proteins are known to exhibit specific inter-
actions with pro-survival BCL2 proteins, including BCL2, BCLXL, BCLW and MCL1 [28].
BIM and PUMA bind to all pro-survival BCL2 proteins; BAD binds selectively to BCL2,
BCLXL and BCLW; and NOXA binds specifically to MCL1 (S1B Fig). To investigate the roles
of pro-survival BCL2 proteins in cells infected with flaviviruses, we generated Huh7 cell lines
stably expressing a BIM-mutant possessing either a binding-defective BH3 domain (BIM-
4EBH3), the BH3 domain from BAD (BIM-BADBH3), or the BH3 domain from NOXA
(BIM-NOXABH3) (S1C and S1D Fig). Although lentivirus-induced expression of BIM-NOX-
ABH3 or BIM-BADBH3 specifically killed Huh7 cells expressing BIM-BADBH3 or BIM-
NOXABH3, respectively, parental and Huh7 cells expressing BIM-4EBH3 were resistant to
killing through the expression of BIM-mutants (S1E Fig). Although no cell death was observed
in parental Huh7 cells, or in cells expressing either BIM-4EBH3 or BIM-NOXABH3, upon
infection with JEV and DENV, cells expressing BIM-BADBH3 showed a significant reduction
in viability at 3 days-post infection (Fig 1B).
To assess which pro-survival BCL2 proteins were responsible for the survival of cells
infected with flaviviruses, the effects of BH3 mimetics on flavivirus-infected cells were deter-
mined. No cytotoxicity was observed in Huh7 cells solely treated with BH3 mimetics at 3days
BCLXL-dependent cell survival upon infection with flaviviruses
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Fig 1. BCLXL participates in the survival of cells infected with flaviviruses. (A) Parental, BAX/BAKDKO (two
clones, #29 and #47) Huh7 cell lines were infected with JEV (MOI = 5). Cell viability was assessed at the indicated time
points. (B) Ectopic expression of BIM-BADBH3 accelerates flavivirus-induced cell death. Parental, BIM-4E,
BIM-BADBH3, and BIM-NOXABH3 Huh7 cells were infected with JEV (MOI = 5; left panel) or DENV (MOI = 3;
right panel). Cell viability was assessed at 3 days post-infection. (C) Huh7 cells infected with either JEV (MOI = 5; left
panel), DENV (MOI = 3; middle panel) or ZIKV (MOI = 1; right panel) were incubated at 37˚C for 2 h; then, culture
medium was replaced with medium containing either of the following: ABT-737, A-1331852, or ABT-199, at the
indicated concentration. Cell viability was assessed at 3 days post-infection. (D) Huh7 cells infected with JEV
(MOI = 5), DENV (MOI = 3) or ZIKV (MOI = 1), and treated with ABT-737 (1 μM). Cell viability was assessed at the
indicated time points. (E) Huh7 cells infected with either JEV (MOI = 5; left panel), DENV (MOI = 3; middle panel) or
ZIKV (MOI = 1; right panel) were treated with ABT-737 (1 μM). Infectious titers in the culture supernatants were
determined by focus-forming assay at the indicated time points. (F,G) Parental and BAX/BAKDKO (two clones, #29
and #47) Huh7 cells were infected with JEV (MOI = 5) and treated with ABT-737 (1 μM). Cell viability was assessed at
3 days post-infection (F). Caspase 3/7 activity was measured at 2 days post-infection (G). (H) Parental and BAX/
BAKDKO (one clone, #47) Huh7 cells were infected with JEV (MOI = 5) or infected with JEV and treated with ABT-
737 (1 μM). Infectious titers in the culture supernatants were determined at the indicated time points. The data in
Figure 1 represent the mean ± SD of two (B,C,F,G) or three (A,D,E,H) independent experiments. Significant
BCLXL-dependent cell survival upon infection with flaviviruses
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post treatment (S1F Fig). Cells infected with JEV, DENV and ZIKV, and treated with either
ABT-737 [29] (targeting BCL2, BCLW and BCLXL) or A-1331852 [30] targeting BCLXL exhib-
ited cell death at 3 days-post infection. In contrast, infected cells treated with ABT-199 [31]
(targeting BCL2) showed no cell death (Fig 1C and S1B Fig). Treatment of ABT-737 (1 μM)
significantly accelerated JEV, DENV and ZIKV induced cell death (Fig 1D). Next, to examine
the roles of BCLXL inhibition on infectious virus production, we quantified viral titres by
using a focus-forming assay. Treatment with ABT-737 (1 μM) exhibited no effect on the infec-
tious particle production of JEV, DENV and ZIKV until 2-days post-infection, but signifi-
cantly reduced the infectious titers at 3 and 4 days post-infection (Fig 1E), suggesting that
induction of cell death by the treatment with ABT-737 in viral infected cells reduces infectious
virus production. We next determined whether ABT-737 treatment induces BAX/BAK-depen-
dent cell death upon infection with flaviviruses. Although parental Huh7 cells exhibited cell
death upon JEV infection and treatment with ABT-737, which activated caspase 3/7, BAX/
BAKDKO cells were resistant to cell death under the same conditions, and no activation of cas-
pase 3/7 was detected (Fig 1F and 1G). In addition, release of cytochrome c was observed in
parental Huh7 cells infected with JEV and treated with ABT-737, but not in BAX/BAKDKO
cells (S1G Fig). Although no increase of infectious particle production was observed in BAX/
BAKDKO cells until 2-days post-infection, three to ten times of increase of infectious titer
compared to parental Huh7 cells was observed in BAX/BAKDKO cells at 3 and 4 days post-
infection (Fig 1H). Collectively, these results suggest that cell death is induced upon infection
with JEV and treatment with ABT-737 through a BAX/BAK-dependent pathway.
BCLXL plays crucial roles in cell survival upon infection with flaviviruses
To confirm the BCLXL-dependent survival of cells upon infection with flaviviruses, we gener-
ated Huh7 cell lines that were deficient in either BCLXL or MCL1 (BCLXKO or MCL1KO)
(Fig 2A). Expression of BIM-BADBH3 and BIM-NOXABH3 killed MCL1KO and BCLXKO
cells, respectively, while expression of BIM-4EBH3 conferred resistance to both parental and
KO cells (Fig 2B). Among the pro-survival proteins of BCL2 protein family, BCLX and MCL1
redundantly suppress activation of both of BAX and BAK. On the other hands, BCL2 and
BCLW had been reported to suppress BAX but not BAK [32–36]. In addition, deficiency of
BCLW in mice developed normally except spermatogenesis in male mice, suggesting that
BCLW is important for apoptosis in testis [37]. To examine the redundancy of BCL2 proteins,
we treated parental, MCL1KO and BCLXKO Huh7 cells with either A-1331852, BCLX-specific
inhibitor or S63845, MCL1 selective inhibitor [24]. MCL1KO Huh7 cells treated with A-
1331852 (1 μM) but not with S63845 (1 μM) and BCLXKO Huh7 cells treated with S63845
(1 μM) but not with A-1331852 (1 μM) induced cell death, while parental Huh7 cells are resis-
tant to the treatment with either compounds but induced cell death by the treatment with both
compounds (S2A Fig). These data suggest that BCLX and MCL1 redundantly suppress activa-
tion of BAX and BAK. The viabilities of BCLXKO cells upon infection with JEV, DENV or
ZIKV were consistently lower than those of parental and MCL1KO Huh7 cells (Fig 2C), and
we confirmed the induction of cell death upon infection with JEV in other independently
established BCLXKO Huh7 cell lines (S2B and S2C Fig). Next, we determined the effect of
BCLX inhibition on plaque formation. Furthermore, Huh7 cells did not form any plaque upon
infection with JEV, DENV and ZIKV, however, BCLXKO Huh7 cells exhibited formation of
differences were determined using Student’s t-test and are indicated by asterisks (P<0.05) and double asterisks
(P<0.01).
https://doi.org/10.1371/journal.ppat.1007299.g001
BCLXL-dependent cell survival upon infection with flaviviruses
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clear plaques upon infection with these viruses (Fig 2D). Taken together, these results indicate
that apoptosis is induced in BCLX-deficient cells upon infection with flaviviruses.
Expression of MCL1 is impaired in cells infected with flaviviruses
BAX/BAK activation is suppressed by pro-survival BCL2 proteins [20]. To investigate how
BCLXL participates in cell survival upon infection with flaviviruses, expression levels of BCLXL
and MCL1 were determined in flavivirus-infected cells. Interestingly, expression of MCL1
decreased upon infection with JEV, DENV and ZIKV, in contrast to the continued stable
expression of other BCL2 family proteins (Fig 3A). No MCL1 protein was detected in the
insoluble fraction of cell lysates (S3A Fig), suggesting that the total amount of MCL1 protein is
decreased by the infection with flaviviruses.
MCL1 has been shown to be a short-lived protein that is degraded by the proteasome
[32,38,39]. Northern blot analysis revealed stable expression of mRNA of MCL1 in JEV-
infected cells (S3B Fig). Reduction of MCL1 protein by JEV infection was slightly restored by
the treatment with a proteasome inhibitor (Ac-Leu-Leu-Nle-Aldehyde, ALLN; (20 μM), how-
ever, the expression level of MCL1 was not recoverable by the inhibition of proteasome (Fig
3B). Moreover, lysosome inhibitor treatment did not restore reduction of MCL1 protein (S3C
Fig), suggesting that JEV infection suppresses host translation resulting in the reduction of
MCL1 protein expression through proteasome-mediated degradation.
Fig 2. BCLXL is a critical survival factor against flavivirus infection. (A) Expression of BCLXL, MCL1, BAK, and
BAX in parental, BCLXKO and MCL1KO Huh7 cells was determined by immunoblotting. (B) Parental, BCLXKO and
MCL1KO Huh7 cell lines were infected with lentiviruses expressing the indicated BIM-mutants, then cultured in the
presence of puromycin. Remaining adherent cells were visualized by Giemsa staining. (C) Deficiency of BCLXL
accelerates cell death upon infection with flaviviruses. Parental, BCLXKO and MCL1KO Huh7 cell lines were infected
with JEV (MOI = 5), DENV (MOI = 3) or ZIKV (MOI = 1). Cell viability was assessed at the indicated time points. (D)
Parental and BCLXKO Huh7 cell lines were infected with JEV (100 FFU), DENV (100 FFU) or ZIKV (500 FFU). At 2
days post-infection, the cells were stained with methylene blue or Giemsa staining. Images are representative of two
independent experiments performed with a culture representative of each cell line (A,B,D). The data represent the
mean ± SD of three independent experiments performed with a culture representative of each cell line (C).
https://doi.org/10.1371/journal.ppat.1007299.g002
BCLXL-dependent cell survival upon infection with flaviviruses
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A previous study showed that MULE (HUWE1) is a unique BH3-containing E3 ubiquitin
ligase that is associated with suppression of MCL1 expression [40]. Suppression of MCL1
expression in JEV-infected MULEKO cells was comparable to MCL1 in JEV-infected parental
Huh7 cells (S3D and S3E Fig). Further, the Skp, Cullin and F-box containing complex (SCF
complex) has also been shown to play a role in MCL1 degradation [41,42]. Although the over-
expression of dominant negative Cullin-1 (DN-CUL1) led to an upregulation of MCL1 in
non-infected cells, infection with JEV still suppressed MCL1 expression (S3F Fig). Addition-
ally, overexpression of the BH3-only protein, NOXA, has been shown to induce suppression of
Fig 3. Expression of MCL1 is impaired in cells infected with flaviviruses. (A) Expression of MCL1 is decreased in
cells infected with flaviviruses. Huh7 cells were infected with either JEV (MOI = 5), DENV (MOI = 3) or ZIKV
(MOI = 1), then incubated with the caspase inhibitor, QVD-OPH (20 μM). Expression of the indicated proteins was
assessed by immunoblotting. (B) Huh7 cells were infected as described above were incubated with QVD-OPH (20 μM)
for 2 days, and further incubated for indicated time in the presence of a proteasome inhibitor (ALLN; 20 μM).
Expression of the indicated proteins was assessed by immunoblotting. (C) JEV infection attenuates cellular protein
synthesis. Total protein synthesis in JEV-infected cells was determined via [35S]-methionine incorporation at indicated
time points (left panel). The data represent the mean ± SD of three independent experiments. Significant differences
were determined using Student’s t-test and are indicated by asterisks (P<0.05) and double asterisks (P<0.01).
Protein synthesis of MCL1 in JEV-infected cells was determined via [35S]-methionine and [35S]-cysteine incorporation
at 2 days post-infection. MCL1 proteins were immunoprecipitated with the appropriate antibody and subjected to
SDS-PAGE (right panel). (D) Huh7 cells infected with JEV (MOI = 5) were incubated with QVD-OPH (20 μM) and
subjected to immunoblotting at 2 days post-infection. (E) Huh7 cell lines stably expressing GFP and D2GFP were
infected with JEV (MOI = 5 or 20) then incubated with QVD-OPH (20 μM) and subjected to immunoblotting at 2
days post-infection. Images (A, B, D, E) are representative of two independent experiments.
https://doi.org/10.1371/journal.ppat.1007299.g003
BCLXL-dependent cell survival upon infection with flaviviruses
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MCL1 expression [32]. Suppression of MCL1 expression in JEV-infected NOXAKO cells was
comparable with MCL1 in JEV-infected parental Huh7 cells (S3G and S3H Fig). Importantly,
expression of MCL1K/R, which is an ubiquitination-defective mutant of MCL1, was still
supressed upon JEV infection (S3I and S3J Fig). The ts20 cells are derived from Balb/c 3T3
cells and possesses a temperature-sensitive ubiquitin-activating E1 enzyme [43]. The ts20 cells
were infected with JEV, then incubated for 6 h at 37˚C (active E1) or 39˚C (inactive E1), 2 days
post-infection. Notably, the expression of p53, but not of MCL1, was restored by inhibition of
E1 (S3K Fig), suggesting that ubiquitination is not involved in the suppression of MCL1 pro-
tein expression in cells infected with JEV.
To examine the effects of JEV infection on protein synthesis, JEV-infected cells were
labelled with [35S]-methionine and [35S]-cysteine. The total amount of protein synthesis was
significantly reduced at both 2 and 3 days post-infection with JEV (Fig 3C, left panel). Addi-
tionally, protein synthesis of MCL1 was significantly reduced by infection with JEV (Fig 3C,
right panel). In addition, expression of CCND1, another short half-life protein [44,45], was
also suppressed by JEV infection (Fig 3D). We hypothesized that expression of short half-life
proteins was non-specifically suppressed upon infection with flaviviruses because labile pro-
teins were constitutively degraded under inhibition of newly protein synthesis. To clarify it, we
generated Huh7 cell lines stably expressing either GFP or D2GFP, a destabilized form of GFP
that contains a PEST sequence [46]. Expression of D2GFP and MCL1 was decreased upon
infection with JEV in a dose-dependent manner at 2 days post infection, in contrast to the sta-
ble expression of GFP (Fig 3E). These results suggest that infection with flaviviruses induces
inhibition of protein translation, leading to a reduction of short half-life proteins such as
MCL1.
Next, to examine the effect of viral proteins on MCL1 expression, we transfected the plas-
mids encoding JEV structural proteins (HA-Core and prM-E), non-structural proteins
(HA-NS1, HA-NS2A, HA-NS2B, HA-NS3, HA-NS4A, HA-NS4B and HA-NS5) and control
vector into Huh7 cells. Expression of viral proteins did not induce suppression of MCL1
expression (S3L Fig). These results suggest that viral propagtion is required for suppression of
MCL1 expression.
Viral propagation is required for the induction of cell death through
suppression of MCL1 expression
To examine the relationship between the suppression of MCL1 expression and a susceptibility
to JEV propagation in other human cell lines, we selected cell lines with high and low suscepti-
bility to JEV infection: IGR-OV1, H522 and SF-268 cells (high susceptibility) and OVCAR5
and HT29 cells (low susceptibility) (Fig 4A). Expression of MCL1 was reduced in the highly
susceptible cell lines upon infection with JEV; in contrast, MCL1 was stably expressed in cell
lines with low susceptibility (Fig 4B). Moreover, cell lines with high susceptibility were killed
by the combination of infection with JEV and treatment with the BH3 mimetic ABT-737
(1 μM) (Fig 4C) or A-1331852 (1 μM) (S4A Fig); in contrast, cell lines with low susceptibility
remained viable when receiving this treatment. In addition, the suppression of MCL1 expres-
sion was enhanced upon infection with JEV (Fig 4D), but suppressed in a dose-dependent
manner by treatment with IFNα (Fig 4E). Further, the decrease in cell viability induced by the
combination treatment was reversed upon treatment with IFNα (Fig 4F). These data suggest
that viral replication is important for suppression of MCL1 expression and suppression of
MCL1 expression is independent on IFN signalling pathway. U937 cells, a human lymphoma
cell line, exhibited high, moderate and low susceptibility to ZIKV, JEV and DENV, respectively
(Fig 4G). Suppression of MCL1 expression was consistent with the degree of susceptibility to
BCLXL-dependent cell survival upon infection with flaviviruses
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each virus at 2 days post infection (Fig 4H). Treatment with the BH3 mimetic ABT-737 (1 μM)
or A-1331852 (1 μM) enhanced cell death in U937 cells that were also infected with ZIKV
(Fig 4I), but not in cells that were also infected with JEV at 3 days post infection (S4B Fig).
Taken together, these data suggest that suppression of MCL1 is required for an efficient viral
propagation.
Fig 4. Viral propagation is required for the induction of cell death through suppression of MCL1 expression. (A)
Susceptibility of human cell lines to JEV. Human cell lines were infected with JEV (MOI = 5) and infectious titers were
determined by focus-forming assay at 3 days post-infection. (B) JEV-susceptible cell lines induce suppression of MCL1
expression. upon infection. Lysates from human cell lines infected with JEV (MOI = 5) were subjected to
immunoblotting at 2 days post-infection. (C) Treatment with ABT-737 induces cell death in the susceptible cell lines
infected with JEV. Human cell lines were infected with or without JEV (MOI = 5) in the absence or presence of ABT-
737 (1 μM) and cell viability was assessed at 3 days post-infection. (D) Dose-dependent suppression of MCL1
expression by JEV infection. Huh7 cells infected with JEV, at an MOI of 10 to 100, were incubated with the caspase
inhibitor, QVD-OPH (20 μM), for 1 day. Cell lysates were subjected to immunoblotting. (E) Interferon treatment
attenuates JEV-induced suppression of MCL1 expression Huh7 cells infected with JEV (MOI = 5) were treated with
interferon-α (IFNα). Cell lysates were subjected to immunoblotting at 2 days post-infection. (F) Interferon treatment
attenuates JEV-induced cell death. Huh7 cells were infected with JEV (MOI = 5) and treated with ABT-737 (1 μM) and
IFNα for 3 days. Cell viability was assessed at 3 days post-infection. (G, H) U937 cells were infected with JEV
(MOI = 20), DENV (MOI = 20) and ZIKV (MOI = 20). (G) Infectious titers were determined by focus-forming assay
at indicated time points, and (H) expression of MCL1 and NS3 was determined by immunoblotting at 2 days post-
infection. (I) U937 cells infected with ZIKV (MOI = 20) were treated with/without ABT-737 (1 μM) or A-1331852
(1 μM) and cell viability was determined at 3 days post-infection. The data represent the mean ± SD of two (A, C, F, G)
or three (I) independent experiments. Images are representative of two independent experiments (B, D, E). Significant
differences were determined using Student’s t-test and are indicated with asterisks (P<0.05) and double asterisks
(P<0.01).
https://doi.org/10.1371/journal.ppat.1007299.g004
BCLXL-dependent cell survival upon infection with flaviviruses
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007299 September 27, 2018 9 / 28
Primary targets of JEV, DENV and ZIKV include haematopoietic and skin cells; therefore,
we next examined the effects of BCLX inhibition during flavivirus infection by using host cells
closer to human infection. Monocyte-derived dendritic cells (MDDCs) have been shown to
be highly susceptible to DENV infection [47]. Treatment with ABT737 (1 μM) significantly
increased cell death in MDDCs that were also infected with DENV (S4C Fig). In addition,
treatment with ABT-737 (1 μM) or A-1331852 (1 μM) significantly increased cell death in
human melanoma cell lines, UACC257 and UACC62, upon infection with JEV (S4D Fig), and
in mouse embryonic fibroblasts (MEFs) infected with JEV, DENV or ZIKV at 2 days post
infection (S4E Fig). These results suggest that suppression of MCL1 expression and induction
of cell death by the treatment with an inhibitor for BCLX are conserved in a variety of human
and mouse cells upon infection with flaviviruses.
Inhibition of BCLXL suppresses viral production and innate immune
responses
An arthropod-borne flavivirus primarily infects dendritic cells, such as Langerhans cells, and
keratinocytes in skin [3]. These infected cells are stimulated and then migrate into the lymph
nodes [48], leading to propagation within the lymphatic system. We hypothesized that the
induction of cell death by BCLXL inhibition in flavivirus-infected cells would accelerate expo-
sure of ‘eat-me’ signal on the surface of the cells and engulfment of infected cells by phago-
cytes, thus inhibiting dissemination of virus infection. To examine the involvement of
phagocytosis in JEV-infected cells treated with the BH3 mimetic ABT-737, we performed an
in vitro phagocytosis assay using peritoneal exudate cells (PECs) as model phagocytes (Fig 5A).
Both of BCLXKO and ABT-737-treated Huh7 cells infected with JEV exhibited a significant
increase of engulfment by PECs at 2 and 3 days post-infection, even though no cell death was
observed at 2 days post-infection (Fig 5B). In contrast, no phagocytosis was observed in JEV-
infected Huh7 cells (Fig 5B).
To examine whether PECs produce chemokines or cytokines upon co-culture with JEV
infected cells, BCLXKO and ABT-737-treated Huh7 cells infected with JEV were overlaid onto
PECs at 1, 2 and 3 days post-infection. Production of chemokines and cytokines in the super-
natants was determined after 24 h of incubation. Significant amounts of chemokines and cyto-
kines were observed in the supernatants of co-cultured PECs with JEV infected but not with
mock-infected Huh7 cells (Fig 5C). Inhibition of BCLXL in JEV-infected Huh7 cells sup-
pressed the production of pro-inflammatory cytokines by PECs, including CCL5, CCL2 and
CXCL10, while no significant difference in the expression of TNF-α and IL-6 was observed
(Fig 5C).
To examine whether infectious particles are released from the co-culture system, the super-
natants were also collected and infectious titers were determined after 24 h of co-culture. Infec-
tious titers were significantly reduced in the supernatants of PECs that were co-cultured with
either BCLXKO or ABT-737-treated Huh7 cells, compared with PECs that were co-cultured
with parental Huh7 cells at 2 and 3 days post-infection with JEV (Fig 5D). Additionally, we
confirmed that JEV could propagate in PECs (S5 Fig). These results suggest that the inhibition
of BCLXL in viral-infected cells accelerates efficient engulfment by phagocytes, thereby sup-
pressing the production of chemokines and infectious particles.
Suppression of BCLXL confers prolonged survival rate after subcutaneous
challenge with JEV
To further examine the biological significance of BCLXL inhibition in virus-infected cells,
mice that were heterozygotic for Bclx were generated using a CRISPR/Cas9 system (S6A Fig),
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because homozygous mice died around E13 due to massive cell death of immature hemopoi-
etic cells and neurons [49]. We obtained F1 mice and generated Bclx+/- mice (F2) by a cross
with wild-type mice. We established three Bclx+/- lines from separate lines of F1 mice (No. 32,
No. 40 and No. 44, S6A Fig). Bclx+/- mice expressed less BCLX protein in the spleen compared
to wild type mice (S6B Fig). We injected lethal amounts of JEV into the footpad of each mouse
Fig 5. Inhibition of BCLXL suppresses viral production and innate immune responses. (A) Schematic of in vitro
phagocytosis assays. BCLXKO cells and Huh7 cells treated with/without ABT-737 (1 μM), were infected with JEV,
labelled with pHrodo green at 1, 2 and 3 days post-infection and overlaid onto PECs pre-incubated overnight.
Infectious titers in the supernatants and engulfment by PECs were determined by focus-forming assay and FACS
analysis, respectively. (B) The percentages of engulfed cells were determined as green fluorescence by FACS analysis
(line, right axis). Viability of JEV-infected BCLXKO cells and JEV-infected Huh7 cells treated with/without ABT-737
(1 μM) was assessed at indicated time points (bar, left axis). The data represent the mean ± SD of two independent
experiments. (C) Suppression of viral propagation by phagocytosis of infected cells. JEV-infected BCLXKO cells and
JEV-infected Huh7 cells treated with/without ABT-737 (1 μM) were overlaid onto PECs at 1, 2 and 3 days post-
infection. Infectious titers in the culture supernatants were determined by focus-forming assay at 1 day after
incubation. The data represent the mean ± SD of three independent experiments performed with a culture
representative of each cell line. (D) Production of TNF-α, CCL5, CCL2, IL-6 and CXCL10 in the supernatants of PEC
cultures (generated as in Figure 5C) was determined by ELISA. The data are representative of three independent
experiments. Significant differences (C, D) were determined using Student’s t-test and are indicated with asterisks
(P<0.05) and double asterisks (P<0.01).
https://doi.org/10.1371/journal.ppat.1007299.g005
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(subcutaneous challenge). Bclx+/- mice exhibited higher survival rates against footpad chal-
lenge with JEV, compared with wild-type mice (Fig 6A). Expression of viral RNA, as well as
Ccl5 and Cxcl10, but not Tnfα, Il6 Ccl2, Ifna and Ifnb, was significantly decreased in the foot-
pads of Bclx+/- mice at 5 days post-infection (Fig 6B and 6C and S6C Fig). In contrast, the
expression of Ccl5, Cxcl10, Tnfα and Il6 was comparable in wild-type and Bclx+/- mice upon
stimulation with Poly(I:C) (Fig 6D and S6D Fig). In addition, oral administration of a clinically
relevant dose of ABT-263 (50mg kg-1), an analogue of the BH3 mimetic ABT-737, conferred
prolonged survival against subcutaneous challenge of JEV (Fig 6E). In contrast, Bclx+/- mice
exhibited similar survival rates and viral RNA production upon intracerebral challenge of
JEV with wild-type mice (Fig 6F and 6G), suggesting that the suppression of virus growth in
peripheral tissues participates in the delay of death and higher percentage of survival in Bclx+/-
mice against JEV challenge. These results suggest that viral propagation within flavivirus-
infected cells can be inhibited by the suppression of BCLXL and subsequent induction of
apoptosis.
Discussion
In this study, we showed that flavivirus infection suppresses expression of labile proteins such
as MCL1 without observable cytotoxicity. Clear cell death, through activation of caspase 3/7,
occurred only when BCLXL was inhibited. Moreover, we showed that treatment with BCLXL
inhibitor (A-1331852) or deficiency of the BCLXL gene induces cell death upon infection with
flaviviruses in several cancer cell lines and primary MEFs. Previous report showed that BCLXL
and MCL1 predominantly inhibit activation of BAK [50], suggesting that a mechanism to
inhibit BCLXL may induce BAK-dependent apoptosis in flavivirus-infected cells, therefore
inhibition of BCLX alone could enhanced cell death in virus-infected cells. In addition, viral
infection decreased MCL1 expression in a variety of human and murine cell lines. Although
the magnitude of suppression of MCL1 expression varied depending on cell line, our data sug-
gest that suppression of MCL1 expression upon propagation of flaviviruses is a common fea-
ture. Legionella infection also induces suppression of MCL1 expression [51]. Although the
molecular mechanisms of MCL1 protein expression in cells infected with Legionella remain
unclear, the suppression of MCL1 through shut off of host translation might be part of the cel-
lular innate response against infection with intracellular pathogens.
MCL1 expression is strictly controlled by transcriptional and post-transcriptional mecha-
nisms [52]. In this study, we showed that flavivirus infection suppresses protein synthesis,
thereby reducing the quantity of proteins with short half-lives, such as MCL1. In addition,
recent reports have shown that infection with flaviviruses represses translation of host pro-
teins, but does not repress viral proteins, which are independent of PKR and eIF2α [53]. Fur-
ther, infection with mammalian orthoreovirus has been shown to inhibit host translation by
compartmentalization of translation machinery within the viral replication complex [54]. Pro-
tein translation is regulated by ribosomal proteins [55]. DENV NS1 protein specifically binds
to the ribosomal protein RPL18 to sequester in perinuclear region and to regulate viral transla-
tion and replication [56]. RPLP1 and RPLP2 identified by genome-wide RNAi screening were
host factors to contribute DENV and yellow fever virus (YFV) infection [57]. We previously
reported that heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) interact with
JEV core protein and facilitate JEV replication through the translocation of core protein from
nucleus to cytoplasm [58]. In addition, infection with HCV has been shown to induce accumu-
lation of adenosine 50-triphosphate in the viral replication complex [59]. Because expression of
JEV proteins exhibited no effect on host translation (S3L Fig), viral propagation might induce
shut-off of host translation by unknown mechanism rather than PKR and eIF2α. On the other
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Fig 6. Suppression of BCLXL confers higher survival rate after subcutaneous challenge with JEV. (A) Wild-type
(n = 30) and Bclx+/- (n = 19) mice were subcutaneously challenged with JEV (4 x 106 FFU). Survival was monitored for
25 days. (B, C) Wild-type (n = 9) and Bclx+/- mice (n = 6) mice were subcutaneously challenged with JEV (4 x 106 FFU)
and footpads were collected at 5 days post-infection. Total JEV RNA (B), and mRNA levels of Ccl5, Cxcl10, Tnfα and
Il6 (C) in the footpads were determined by qPCR. (D) Wild-type (n = 7) and Bclx+/- mice (n = 5) were subcutaneously
injected with Poly(I:C) (10 μg) suspended in 50 μL PBS and footpads were collected at 12 h post-inoculation.
Expression of Ccl5 and Cxcl10 in the footpads of wild-type and Bclx+/- mice was determined by qPCR. (E) C57BL/6
mice that were subcutaneously infected with JEV (4 x 106 FFU) were orally treated with 50mg kg-1 of the BH3 mimetic
ABT-263 (n = 15) or vehicle (n = 31) at 2 days post-infection. Survival was monitored for 25 days. (F, G) Wild-type
(n = 13) and Bclx+/- mice (n = 15) were intracerebrally infected with JEV (1 x 105 FFU). Survivals was monitored for 10
days (F) and viral RNA was determined by qPCR (G). The relative expression (B, C, D) in Bclx+/- mice was represented
as the ratio of each value per leg to the corresponding value of wild-type mice using the standard curve method. The
data represent each value and mean ± SD. Significant differences (B, C) were determined using Student’s t-test and are
indicated by asterisks (P<0.05) and double asterisks (P<0.01). Significant differences (A, F) were determined using
the log-rank test and are indicated by asterisks (P<0.05) and double asterisks (P<0.01).
https://doi.org/10.1371/journal.ppat.1007299.g006
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hand, viruses counteract host responses through the rearrangement of membrane structures to
restrict the components of translation machinery into the viral replication complex.
Our data indicate that inhibition of BCLXL in viral-infected cells activates phagocytosis by
macrophages, leading to the suppression of infectious particle production and suggest that
inhibition of BCLXL function as an anti-viral effect. Although the survival of mice that were
intracerebrally inoculated with JEV was not significantly different between wild-type and
Bclx+/- mice, Bclx+/- mice showed higher survival rate against subcutaneous challenge by JEV,
compared with their wild-type counterparts. Our data suggest that phagocytosis plays an
important role in removing apoptotic.
JEV-infected cells after BCLX inhibition. Microglial cells, a resident subset of macrophages
in the brain, and hematogenous macrophages play a role in phagocytosis in the brain and
peripheral tissues, respectively. These two-types of macrophage have phagocytotic activity but
have some different functions [60]. The functional difference of the microglia and hematoge-
nous macrophages might be involved in the phagocytosis-mediated removals of virus-infected
cells by BCLX inhibition in intracerebral or subcutaneous infection. Collectively, these data
suggest that apoptosis induced by inhibition of BCLXL attenuates viral virulence in peripheral
tissues.
The production of cytokines and chemokines during viral infection is strongly associated
with viral pathogenicity [61], especially, deficiency of several chemokine receptors such as
CCR5 and CXCR3 promotes severity of pathogenicity against WNV infection [62]. We
showed that the inhibition of BCLXL specifically induces apoptosis and impaired production
of CCL5 and CXCL10, which are ligands for CCR5 and CXCR3, respectively, during in vitro
and in vivo viral infections. Impairment of these chemokines may contribute attenuation of
pathogenicity by inhibition of BCLXL. In addition, administration of the BH3 mimetic, ABT-
263, into wild-type mice increased survival rate after subcutaneous JEV challenge. We also
showed that production of viral RNA and chemokines was impaired in Bclx+/- mice (Fig 6B
and 6C). In addition, treatment of wild type and Bclx+/- mice with polyIC exhibited no effect
on chemokine induction (Fig 6D). These data suggest that enhanced apoptosis in Bclx+/- and
ABT-263-treated mice upon infection with JEV promotes engulfment by phagocytes, which
leads to reduces viral production and the number of leukocytes migrating to the infection site
due to lower production of chemokines.
Treatment with inhibitors of BCLX such as ABT-263 was demonstrated to cause thrombo-
cytopenia due to their neutralization of BCLXL in circulating platelets without bone marrow
toxicity [30,63,64]. It was also demonstrated that thrombocytopenia induced by ABT-263 is
dose-dependent and reversible effect [64], therefore it is possibility to control thrombocytope-
nia by appropriate terms of treatment or amounts of BCLX inhibitors [65,66]. It is also another
possibility to develop the drug delivery system to virus-infected cells to avoid the unexpected
side effects. Further studies are needed to use inhibitors of BCLX for antiviral therapy.
Based on these results, we propose the model as shown in Fig 7 to explain the regulation of
BCL2 family proteins upon infection with flaviviruses. In this study, we showed that infection
with flaviviruses reduces expression of MCL1 but remaining BCLXL delayed apoptosis in
infected cells. This delay of apoptosis is crucial for viral dissemination to neighbouring cells,
leading to high pathogenicity. On the other hand, impairment of BCLXL accelerates apoptosis
in cells infected with flavivirus and dissemination is reduced by the removal of infected cells
through phagocytosis, leading to local infection and low pathogenicity in vivo.
In conclusion, we have demonstrated that BCLXL is a critical cell survival factor during
infection with flaviviruses, and that inhibition of BCLXL by treatment with BH3 mimetics
restricts the production of infectious particles in vitro and in vivo. We showed that expression
of pro-survival MCL1 is reduced upon infection with flaviviruses. Although further studies are
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needed to clarify the molecular mechanisms, the translational suppression induced by viral
infection is suggested to participate in the instability of unstable proteins including MCL1.
Bclx+/- mice exhibited impairment of pathogenicity to JEV infection, together with the
enhanced viral clearance by phagocytosis of infected cells through the stimulation of apoptosis
by BCLXL inhibition. In addition, Bclx+/- mice, and wild-type mice that received ABT-263,
exhibited prolonged survival rates after JEV challenge compared with untreated wild-type
mice. These data suggest that BCLXL may serve as a novel antiviral target that facilitates sup-
pression of the propagation of a broad range of the family Flaviviridae viruses.
Materials and methods
Viruses and cell lines
Huh7, 293T, U937, and Vero cells were obtained from the National Institute of Infectious Dis-
eases and cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10%
Fig 7. Proposal model of induction of apoptosis via BCLXL inhibition. Flavivirus infection induces reduction of
MCL1 protein, but BCLXL delayed apoptosis in normal cells, and virus is able to spread to neighboring cells, leading to
high pathogenicity. On the other hand, inhibition of BCLXL accelerates apoptosis upon infection and viral
dissemination is inhibited by removal of infected cells by phagocytosis.
https://doi.org/10.1371/journal.ppat.1007299.g007
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fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin. IGR-OV1, SF268,
H522, OVCAR5, HT29, UACC257, UACC62 and ts20 were provided by the Walter & Eliza
Hall Institute and maintained in RPMI1640 supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin and 100 μg/ml streptomycin. The MEFs were obtained from E14.5
embryos and maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/
ml penicillin and 100 μg/ml streptomycin. JEV (AT31 strain), DENV (H241 strain) and ZIKV
(MR766-NIID strain) were propagated in C6/36 cells. Infectious titers of JEV, DENV and
ZIKV were determined by focus-forming assay. Mouse monoclonal antibodies against JEV/
DENV/ZIKV NS3 (#578, #1791);[58] were used to visualize the focuses.
Plasmids
BIM, BIM-BADBH3, BIM-NOXABH3 and BIM-4EBH3 [28] were amplified by Tks Gflex
DNA Polymerase (Takara-Bio) and cloned into an FUIPW lentiviral transfer vector [67] by
using an In-Fusion HD cloning Kit (Takara-Bio). The MCL1K/R gene was synthesized by
Thermo Fisher Scientific (GeneArt Strings), amplified and cloned into an FUIPW vector or a
pCAGGS vector [68]. The cDNA of D2GFP [46] was synthesized (Integrated DNA Technolo-
gies (IDT)) and cloned into an FUIPW vector. pCAG-HA-Ubiquitin was previously described
[69]. Plasmids encoding HA-tagged JEV Core and NS proteins (pCAGPM-HA-NS) were pre-
viously described [58,70]. Plasmids encoding JEV prM-E protein was previously described
[71]. pcDNA3-DN-hCUL1-FLAG was obtained from Addgene (#15818). The pSPT18 was
obtained from Dr. Kamitani. For the CRISPR/Cas9 system, the plasmids of pX330 (#42230)
and pCAG EGxxFP (#50716) were obtained from Addgene. All sgRNAs are listed in Appendix
S1 Table. The lentivirus packaging vectors, pMDLg/pRRE, pRSV-Rev and pCMV-VSV-G,
were obtained from Addgene. The sequences of all plasmids used in this study were confirmed
by using an ABI Prism 3130 genetic analyzer (Applied Biosystems).
Lentivirus production
To generate lentiviruses, 293T cells were transfected with transfer vectors, pMDLg/pRRE,
pRSV-Rev and pCMV-VSV-G, using polyethylenimine (PEI; MW: 25,000; Polysciences Inc.),
and the culture supernatants collected at 3 days post-transfection were passed through a
0.45-mm filter. Culture supernatants containing the lentiviruses were inoculated into target
cells seeded on 6-well plates using Polybrene (Sigma) and were centrifuged at 2,500 rpm for 45
min at 32 ˚C.
Antibodies and reagents
The following antibodies were used: anti-JEV/DENV/ZIKV NS3 monoclonal antibody (#578,
#1791, 1:1000 dilution) [58], anti-ACTIN mouse monoclonal antibody (A2228; Sigma, 1:5000
dilution), horseradish peroxidase-conjugated anti-FLAG mouse monoclonal antibody (clone
M2; Sigma, 1:1000 dilution), anti-HA rat monoclonal antibody (clone 3F10; Roche, 1:1000
dilution), mouse anti-cytochrome c (BD 556433, 1:1000 dilution), rabbit polyclonal antibodies
to MCL1 (sc-819; Santa Cruz, 1:1000 dilution, 600-401-394; Rockland, 1:5000 dilution), mouse
monoclonal antibodies to BCLXL (BD 610747, 1:1000 dilution, BD 610212, 1:1000 dilution),
BAK (8F8, 1:1000 dilution), BAX (21C10-23-8-3, 1:1000 dilution), CYCLIN D1 (BD 556470,
1:1000 dilution), FKBP8 [72] (1:1000 dilution), MULE (NB100-652; Novus Biologicals, 1:1000
dilution), p62 (M162-3; MBL, 1:1000 dilution), p53 (1C12; Cell Signaling Technology, 1:1000
dilution), ABT-737, ABT-199 and A-1331852 were synthesized by Walter & Eliza Hall Insti-
tute. ABT-263 was obtained from Synkinase. S63845 was obtained from Active Biochem.
ALLN (A6185) and bafilomycin A1 (B1793) were obtained from Sigma, QVD-OPH (sc-
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222230) was obtained from Santa Cruz Biotechnology and Digitonin (#300410) was obtained
from Calbiochem, E64d (4321-v), and pepstatin A (4397-v) were obtained from Peptide Insti-
tute, Inc. human IL-4 (200–04) and GM-CSF (300–03) were obtained from peprotech. Poly(I:
C) (tlrl-pic) was obtained from invivogen.
Establishment of gene-knockout cell lines by using the CRISPR/Cas9
system
Knockout Huh7 cell lines were established by using CRISPR/Cas9 as described previously
[73]. The plasmids of pX330 (#42230) and pCAG EGxxFP (#50716) were obtained from
Addgene. The target sequences of each gene are summarized in S1 Table. Genomic DNAs of
Huh7 were amplified and cloned into pCAG EGxxFP. Huh7 cells were transfected with pX330
and pCAG EGxxFP and incubated for 1 week. GFP-positive Huh7 cells were sorted by FACS
and formed a single colony. Gene deficiency was confirmed by sequencing and Western
blotting.
Western blotting
Cell lysates were prepared by incubation in Onyx lysis buffer consisting of 20 mM Tris-HCl
(pH 7.4), 135 mM NaCl, 1% Triton X-100, 1% glycerol and protease inhibitor cocktail tablets
(Roche Molecular Biochemicals) for 15 min at 4˚C. Cell lysates were centrifuged at 13,000 rpm
for 5 min at 4˚C after sonication. Protein concentrations of supernatants of cell lysates were
determined by using Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad). The super-
natants were incubated with sample buffer at 95˚C for 5 min. The samples (50 μg of proteins)
were resolved by SDS-PAGE (Novex, Life Technologies) and transferred onto nitrocellulose
membranes (iBlot, Life Technologies). These membranes were blocked with PBS containing
5% skim milk, and then incubated with primary antibody at 4˚C overnight. After washing, the
membrane was reacted with HRP-conjugated secondary antibody at room temperature for 2
h. The immune complexes were visualized with Super Signal West Femto substrate (Pierce)
and detected by an LAS-3000 image analyzer system (Fujifilm).
Northern blotting
Total RNA was subjected to electrophoresis in 1.2% agarose-formaldehyde gel and morpholi-
nepropanesulfonic acid buffer. rRNA was visualized by ethidium bromide staining, and elec-
trophoresed RNA was transferred onto a positively charged nylon membrane (Cat No. 11 417
240 001; Roche). Full-length MCL1 cDNA was amplified and cloned into pSPT18 digested by
EcoRI using an In-Fusion HD cloning kit (Clontech), an RNA probe was synthesized by using
a digoxigenin (DIG) RNA labeling kit (Roche), and hybridization and detection were per-
formed by using a DIG Northern Starter kit (Roche) according to the manufacturer’s proto-
cols. The signals were detected by an LAS-3000 image analyzer system (Fujifilm).
Cell death assay
Huh7 cells (2x104 cells) were seeded on 12-well plates (Greiner) and incubated for 1 day. JEV,
DENV or ZIKV were infected for 2 h and the culture medium was changed. At each time
point, supernatants containing cells and adherent cells were collected and stained with 5 μg/
mL of propidium iodide (PI, P4170; Sigma). Cell viability was determined by flow cytometry
analyses (BD) and FlowJo software (FlowJo, LLC).
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Caspase activity assay
Huh7 and BAX/BAKDKO (#29 and #47) cells were infected with JEV (MOI = 5) and incu-
bated at 37˚C for 2 days. Caspase 3/7 activity was determined by using Caspase 3/7Glo (Pro-
mega) according to the manufacturer’s protocol.
Clonogenic assay
Cells (2x105) seeded on 6-well plates (Greiner) were infected with lentiviruses expressing BIM,
BIM-BADBH3, BIM-NOXABH3 and BIM-4E at one day after incubation, expanded into 10
cm dishes (Greiner) at 2 days post-infection, and cultured with medium containing 1 μg/ml of
puromycin for 1 week with a change of culture medium every 2 days. The remaining cells were
washed with PBS, incubated with 5 mL of Giemsa’s azur-eosin-methylene blue solution
(Merck Milipore: 109204) for 1 h at room temperature, and washed in water.
Ubiquitination assay
293T cells (2x106) seeded on 10 cm dishes were transfected with 1.0 μg of either pCAGGS
MCL1 or pCAGGS MCL1K/R and 0.05 μg of HA-ubiquitin plasmid by using PEI after 12 h of
incubation. After 2 days, cells were treated with proteasome inhibitor (20 μM, ALLN) for 6 h
and lysed with buffer A (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 1% sodium deoxycholate, 1% SDS) supplemented with 1 mM sodium fluoride and pro-
tease inhibitor cocktail tablets (Roche) on ice for 30 min and sonicated. Cell lysates (200 μl)
were diluted with buffer A lacking SDS, incubated with anti-HA antibody (HA.11, 2 μl per
sample; Covance) at 4 ˚C for 90 min and then further incubated with Protein G Sepharose 4B
(GE Healthcare) at 4 ˚C for 90 min. The beads were washed five times in buffer A lacking SDS
and eluted in sample buffer after incubation at 95˚C for 5 min. Denatured samples were
resolved by SDS-PAGE and immunoblotting.
In vitro cytochrome c release assay
Huh7 and BAX/BAKDKO (#47) cells seeded on 10 cm dishes were infected with JEV
(MOI = 5) and treated with ABT-737 (1μM) for 1 h at 37˚C. Cells (1.5 x106) were pelleted at 2
days post-infection, resuspended in 100 μl of permeabilization buffer consisting of 250 mM
sucrose, 1 mM EDTA, 1 mM EGTA, 5 mM MgCl2, 100 mM KCl, 20 mM Hepes, and 0.025%
of digitomin (#300410; Calbiochem) supplemented with protease inhibitor cocktail tablets,
and incubated on ice for 5 min. Cell lysates were centrifuged by 13,000 rpm at 4˚C for 5 min
and the supernatants were collected as a soluble fraction. Pellets were resuspended with Onyx
lysis buffer and then incubated on ice for 30 min, and the supernatants were collected as a pel-
let fraction. Both lysates were incubated with sample buffer at 95˚C for 5 min, and denatured
samples were resolved by SDS-PAGE and immunoblotting.
Plaque-formation assay
Huh7 and BCLXKO Huh7 cells seeded onto 12-well or 24-well plates were inoculated with
serially diluted virus and incubated for 2 h. The supernatants were removed and culture
medium containing 1% methylcellulose was overlaid onto the cells. After 2 days of incubation,
cells were fixed with 4% paraformaldehyde and visualized by staining with methylene blue
(Sigma) or Giemsa’s azur-eosin-methylene blue solution (Merck Milipore: 109204) for 1 h at
room temperature, and washed in water.
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[35S] Methionine-labeling of proteins
Huh7 cells or JEV-infected cells were seeded on 12-well plates and washed twice with DMEM
(deficient in methionine and cysteine; Gibco 21013024), then incubated with [35S] methionine
and [35S] cysteine (EasyTag Express35S Protein labeling mix, Perkin Elmer) in DMEM without
methionine and supplemented with 10% dialyzed FBS, 100 U/ml penicillin and 100 μg/ml
streptomycin for 15 min at 1, 2 and 3 days post-infection. Labeled cells were washed three
times with cold PBS, then lysed with 200 μl/well radioimmunoprecipitation (RIPA) buffer, and
the cell lysates were centrifuged at 13,000 rpm for 10 min at 4˚C. Protein concentrations were
determined by using Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad). Clear-sol
(900 μl; Nakalai Tesque) was mixed with each supernatant (100 μl), and measured with a liquid
scintillation counter (LS6500; Beckman Coulter). For detection of synthesis of MCL1 protein,
Huh7 cells were seeded on 10 cm dishes, infected with JEV (MOI = 5) and incubated for
2days. These cells were washed twice with DMEM (deficient in methionine and cysteine;
Gibco 21013024), then incubated with [35S] methionine and [35S] cysteine (EasyTag
Express35S Protein labeling mix, Perkin Elmer) in DMEM without methionine and supple-
mented with 10% dialyzed FBS, 100 U/ml penicillin and 100 μg/ml streptomycin for 15 min at
37˚C. Cell lysates were prepared by incubation in Onyx lysis buffer for 15 min at 4˚C. Cell
lysates were centrifuged at 13,000 rpm for 5 min at 4˚C. Protein concentrations were deter-
mined by using Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad). Same amounts of
cell lysates were incubated with 2μL of MCL1 antibody at 4˚C for 90 min and then further
incubated with Protein G Sepharose 4B (GE Healthcare) at 4˚C for 90 min. The beads
were washed three times with Onyx lysis buffer, boiled at 95˚C for 5 min, and subjected to
SDS-PAGE. The 35S-labeled proteins were visualized by using a Fujifilm bioimaging analyzer
(FLA-7000, Fujifilm).
Quantitative real-time PCR (qRT-PCR)
RNA was extracted by using ISOGEN II (Nippon Gene), and cDNAs were synthesized from
the total RNA using a High Capacity RNA-to-cDNA kit (Applied Biosystems) according to the
manufacturer’s instructions. JEV RNA were quantified using a TaqMan RNA-to-Ct 1-Step Kit
and the ViiA7 real-time PCR system (Life Technologies). The primers of JEV were 50-GGGTC
AAAGTCATTTCTGGTCCATA’ and 50-TCCACGCTGCTCGAA’. The following probe were
used: for JEV, 50-6-FAM/ATGACCTCG/ZEN/CTCTCCC/-30IABkFQ;. mRNAs of Il6, Tnfα,
Ccl5, Cxcl10, Ccl2, Ifna, Ifnb and β-actin were used for quantification of mRNA expression by
using a Power SYBR green RNA-to-Ct 1-Step kit and theViiA7 real-time PCR system (Life
Technologies). The following primers were used: for Il6 50-CCACTTCACAAGTCGGAGGC
TTA-30 and 50-GCAAGTGCATCATCGTTGTTCATAC-30 Tnfα 50-CAGGAGGGAGAACA
GAAACTCCA-30 and 50-CCTGGTTGGCTGCTTGCTT-30, Ccl5 50-AGATCTCTGCAGCTG
CCCTCA-30 and 50-GGAGCACTTGCTGCTGGTGTAG-30, Cxcl10 50-ACACCAGCCTGG
CTTCCATC-30 and 50-TTGGAGCTGGAGCTGCTTATAGTTG-30, Ccl2 (50-GCATCCACG
TGTTGGCTCA-30 and 50-CTCCAGCCTACTCATTGGGATCA-30, Ifna1 50-AGCCTTGA
CACTCCTGGTACAAATG-30 and 50-TGGGTCAGCTCACTCAGGACA-30 Ifnb1 50-ACAC
CAGCCTGGCTTCCATC-30 and 50-TTGGAGCTGGAGCTGCTTATAGTTG-30, β-actin 50-
TTGCTGACAGGATGCAGAAG-30 and 50-GTACTTGCGCTCAGGAGGAG- 30.
Human monocyte-derived DCs (MDDCs)
Human monocyte-derived DCs were generated from healthy human blood donors using Lym-
phocyte Separation Solution (nacalai tesque). CD14+ cells were isolated after Ficoll-Hypaque
gradient centrifugation using MACS CD14+ magnetic beads with FcR Blocking Reagent
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(Miltenyi Biotech) as manufacturer’s instructions. These human monocytes (5x105 cells) were
seeded on 24 well plates and differentiated into naive DCs by culturing for 4 days in differenti-
ated medium, Iscove’s Modified Dulbecco’s Media containing 10% fetal bovine serum (FBS),
100 U/ml penicillin, 100 μg/ml streptomycin 10 μg/ml human IL-4 (PeproTech) and 50 μg/ml
human granulocyte-macrophage colony-stimulating factor (GM-CSF) (PeproTech). MDDCs
(4 x 105 cells) were infected with DENV (MOI = 3) for 60 min at 37˚C. Cells were then pelleted
at 2,000 rpm for 5 min and resuspended in 1000 μl of differentiated medium.
Generation of Bclx+/- mice
Bclx+/- mice were generated as previously described [74] using a BDF1 genetic background.
The pX330 containing an sgRNA against the mouse Bclx gene (S1 Table) was injected into
mouse zygotes and transplanted into pseudopregnant female mice. The obtained mice (F1)
were crossed with wild type mice and F2 mice were analyzed by sequencing. We obtained
three Bclx+/- lines from different F1 mice and kept them by crossing with wild type mice.
Phagocytosis assay
Peritoneal exudate cells (PECs) were isolated from C57BL/6 (Japan SLC, Inc.) mice intraperi-
toneally injected with 2 ml of 3% thioglycolate solution by rinsing the peritoneal cavity with 5
ml of PBS. Cells were pelleted by 1,500 rpm at 4 ˚C for 5 min and suspended in RPMI supple-
mented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin, and cultured on 10
cm culture dishes. After 2 h of incubation, adherent cells were collected and seeded in culture
medium containing 10 ng/ml human IL-4 (PeproTech), then incubated overnight at 37 ˚C.
Huh7 and BCLXKOHuh7 cells infected with JEV were incubated with pHrodo green (10 μM;
Life Technologies) at 37 ˚C for 30 min and washed twice with culture medium. Labeled-cells
were overlaid onto PECs and incubated at 37 ˚C for 45 min. PECs were washed with culture
medium three times to remove non-adherent cells. The amounts of engulfed PECs were deter-
mined by FACS (Becton Dickinson). Labeled cells overlaid on PEC were incubated at 37 ˚C
for 2 h and replaced with fresh medium. Infectious titers and cytokine production in the
supernatants were determined after 24 h of incubation.
ELISA
The productions of mouse IL-6 (KMC0061, Novex), TNF-α (KMC3010, Novex), CCL5
(NMR00, R&D Systems), CCL2 (MJE00, R&D Systems) and CXCL10 (BMS6018, Thermo
Fisher Scientific) were quantified by ELISA according to the manufacturer’s protocol.
In vivo experiments
Three-week-old mice were anaesthetized by intraperitoneal administration of 0.75 mg kg-1
medetomidine (Meiji Seika), 4 mg kg-1 midazolam (Sandoz) and 5 mg kg-1 butorphanol tar-
trate (Meiji Seika). JEV (2x106 FFU/50 μl) was injected subcutaneously into both rear footpads
(4x106 FFU in total). JEV (1x105 FFU) was also intracerebrally injected. The survival of the
mice was monitored for 25 days. To collect the brain tissues, mice were sacrificed at the end-
point and then recorded as dead.
Dosing
Dosing of ABT-263 was performed as previously described [51,64]. Briefly, ABT-263 was for-
mulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG for dosing. The
mice were dosed orally once a day for 2 to 8 days with vehicle or 50mg kg-1 ABT-263.
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Ethics statement
All animal experiments conformed to the Guidelines for the Care and Use of Laboratory Ani-
mals, and were approved by the Institutional Committee of Laboratory Animal Experimenta-
tion (Research Institute for Microbial Diseases, Osaka University. Project number: H27-06-0).
All healthy donors provided oral consent and were properly informed of the risks of the study.
Statistical analysis
The statistical analyses were performed using GraphPad Prism (GraphPad Prism Software,
Inc.). Significant differences were determined using Student’s t-test and are indicated with
asterisks (P<0.05) and double asterisks (P<0.01) in each figure. Significant differences of
in vivo survival data were determined using log-rank test and are indicated with asterisks
(P<0.05) and double asterisks (P<0.01) in each figure.
Supporting information
S1 Fig. Establishment of Huh7 cell lines expressing each BIM-mutants and cell toxicity of
each BH3-mimetics. (A) Establishment of BAX/BAKDKO Huh7 cell lines. Cell lysates of
BAX/BAKDKO Huh7 cell lines (clones #29 and #47) were subjected to immunoblotting
using antibodies against the indicated proteins. Images are representative of two independent
experiments. (B) Interactions of BCL2 proteins with BH3-only proteins and BH3 mimetics.
BH3-only proteins BIM and PUMA bind to all pro-survival BCL2 proteins; BAD binds to only
BCL2, BCLXL and BCLW; and NOXA binds only to MCL1. The binding properties of BH3
mimetics ABT-737 and ABT-263 are the same as those of BAD. In contrast, BH3 mimetics
ABT-199 and A-1331852 specifically bind to BCL2 and BCLXL, respectively. (C) Interactions
of BCL2 proteins with BIM-mutants. BIM binds to all pro-survival BCL2-like proteins (BCL2,
BCLXL, BCLW and MCL1). BIM-BADBH3 binds only to BCL2, BCLXL and BCLW. BIM-
NOXABH3 binds only to MCL1. BIM-4E was produced by the replacement of four hydropho-
bic residues in the BH3 region of BIM with glutamate residues; the resulting mutant was
incapable of binding to any BCL2 protein. “BCL” represents BCL2, BCLXL and BCLW. (D)
Establishment of Huh7 cell lines stably expressing BIM-mutants. Cell lysates from Huh7 cell
lines stably expressing BIM-mutants were subjected to immunoblotting using antibodies
against the indicated proteins. Images are representative of two independent experiments. (E)
Characterization of Huh7 cell lines stably expressing BIM-mutants. Huh7 cell lines stably
expressing BIM-mutants were infected with lentiviruses expressing the indicated BIM-
mutants; then, cell viability was assessed by PI staining and FACS analysis at 2 days post-infec-
tion. The data represent the mean ± SD of two independent experiments performed with a cul-
ture representative of each cell line. (F) Huh7 cells were treated with ABT-737, A-1331852 or
ABT-199 at the indicated concentrations. Cell viability was assessed at 3 days post-treatment.
The data represent the mean ± SD of two independent experiments. (G) Parental and BAX/
BAKDKO (clone #47) Huh7 cell lines were infected with JEV (MOI = 5) and treated with
ABT-737 (1 μM). Cells were collected at 2 days post-infection, permeabilized with digitonin
and fractionated into pellet (P) and supernatant (S) fractions. Each fraction was subjected by
immunoblotting using antibodies against the cytochrome c (Cyt c), BAK, β-ACTIN (cytosolic
marker) and FKBP8 (membrane fraction marker).
(TIF)
S2 Fig. Establishment of several independent cell clones of BCLXKO Huh7 cells are sensi-
tive flavivirus infection. (A) Parental, BCLXKO and MCL1KO Huh7 cell lines were treated
with/without A-1331852 (1 μM), S63845 (1 μM) or combination of A-1331852 (1 μM), S63845
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(1 μM). Cell viability was assessed at 6h post-treatment. The data represent the mean ± SD of
two independent experiments. (B) Establishment of BCLXKO Huh7 cell lines. Cell lysates of
parental and BCLXKO Huh7cell lines (#1, #2, #26, #41, #42) were subjected to immunoblot-
ting, using antibodies against the indicated proteins. Images are representative of two indepen-
dent experiments performed with a culture representative of each cell line. (C) Deficiency
of BCLXL accelerates cell death upon infection with JEV. Parental and BCLXKO Huh7 cell
lines (clones #1, #2, #26, #41, #42) were infected with JEV (MOI = 5) and cell viability was
assessed by PI staining, and by FACS analysis, at 3 days post-infection. The data represent the
mean ± SD of two independent experiments performed with a culture representative of each
cell line.
(TIF)
S3 Fig. Additional information on the mechanism of suppression of MCL1 expression. (A)
Huh7 cells were infected with JEV (MOI = 5), incubated with a caspase inhibitor, QVD-OPH
(20 μM), for 2 day. Cell lysates were separated into supernatant (S) and pellet (P) fractions by
centrifugation. Fractions were subjected to SDS-PAGE and immunoblotting. (B) Quantity of
MCL1 mRNA in Huh7 cells infected with JEV. Total RNA was extracted from Huh7 cells
infected with JEV (MOI = 5) at the indicated time points, then subjected to Northern blotting.
(C) Huh7 cells were infected with JEV (MOI = 5), incubated with QVD-OPH (20 μM) for 36
h, and then incubated for 12 h in the presence of a lysosome inhibitor, either E64d (30 μM)/
pepstatin A (1.5μM; E64d & PEP) or bafilomycin (BAF; 10 nM). (D) Establishment of
MULEKO Huh7 cell lines. Cell lysates of parental and MULEKO (clones #15 and #36) Huh7
cell lines were subjected to immunoblotting using antibodies against the indicated proteins.
Images are representative of two independent experiments performed with a culture represen-
tative of each cell line. (E) MULE is not required for suppression of MCL1 expression in JEV-
infected cells. Parental and MULEKO (clones #15 and #36) Huh7 cell lines infected with JEV
(MOI = 5) were incubated with QVD-OPH (20 μM). Cells were subjected to immunoblotting
using antibodies against the indicated proteins at 2 days post-infection. Images are representa-
tive of two independent experiments performed with a culture representative of each cell line.
(F) Effect of Cullin1 inhibition on suppression of MCL1 expression upon JEV infection. Huh7
cells transfected with empty vector or DN-CUL1 plasmid were infected with JEV (MOI = 5) at
1 day post-transfection in the presence of QVD-OPH (20 μM). Cell lysates were subjected to
immunoblotting using antibodies against the indicated proteins at 2 days post-infection.
Images are representative of two independent experiments. (G) Establishment of NOXAKO
Huh7 cell lines. Parental and NOXAKO (clones #19 and #21) Huh7 cell lines were infected
with JEV and total RNAs were extracted at 2 days post-infection. RT-PCR was performed
using the following primers: for NOXA, 50-GTTTGTCTCCAAATCTCCTGAGTT-30 and 50-
CGGAGATGCCTGGGAAGAAG-30; and for GAPDH, 50-TGTAGTTGAGGTCAATGA
AGGG-30 and 50-ACATCGCTCAGACACCATG-30. Images are representative of two inde-
pendent experiments performed with a culture representative of each cell line. (H) NOXA
is not necessary for suppression of MCL1 expression induced by JEV infection. Huh7 and
NOXAKO cell lines (clones #19 and #21) infected with JEV (MOI = 5) were incubated with
QVD-OPH (20 μM), then subjected to immunoblotting using antibodies against the indicated
proteins at 2 days post-infection. Images are representative of two independent experiments
performed with a culture representative of each cell line. (I) Wild-type and mutant MCL1
(MCL1K/R), in which all Lys residues were replaced with Arg, were co-transfected with
HA-Ubiquitin into 293T cells. Cell lysates were immunoprecipitated using an anti-HA anti-
body and precipitates were subjected to immunoblotting as indicated. Images are representa-
tive of two independent experiments. (J) MCL1KO Huh7 cell line expressing either wild type
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or mutant MCL1 replaced all lysine residues to Arg (MCL1K/R) were infected with JEV
(MOI = 20) and incubated with QVD-OPH (20 μM). Cells were subjected to immunoblotting
at 2 days post-infection. (K) ts20 temperature-sensitive ubiquitin-activating E1 enzyme cells
infected with JEV (MOI = 100) were incubated with QVD-OPH (20 μM). At 2 days post-infec-
tion, cells were either incubated at 37˚C (active E1) or 39˚C (inactive E1) for 6 h. Cell lysates
were subjected to immunoblotting using antibodies against the indicated proteins. Images are
representative of two independent experiments. (L) Cell lysates of Huh7 cells transfected with
the expression plasmids were harvested at 2 days post-transfection and subjected to immuno-
blotting using antibodies against the indicated proteins. Images are representative of two inde-
pendent experiments.
(TIF)
S4 Fig. Suppression of MCL1 proteins and cell death by treatment with ABT-737 or A-
1331852 in JEV infected skin cells. (A) Treatment with A-1331852 induces cell death in the
susceptible cell lines infected with JEV. Viability of human cell lines infected with/without JEV
(MOI = 5) in the absence or presence of A-1331852 (1 μM) was assessed at 3 days post-infec-
tion. Data are the mean of two independent experiments, represented as the mean ± SD. (B)
U937 cells infected with JEV (MOI = 20) were treated with ABT-737 (1 μM) and cell viability
was determined at 3 days post-infection. Data are the mean of four independent experiments,
represented as the mean ± SD. (C) MDDCs infected with or without DENV (MOI = 3) were
treated with ABT-737 (1 μM) and cell viability was determined at 3 days post-infection. (D)
UACC257 and UACC62 cells infected with or without JEV (MOI = 20) were treated with
ABT-737 (1 μM) or A-1331852 (1 μM) and cell viability was determined at 3 days post-infec-
tion. Data are the mean of four independent experiments, represented as the mean ± SD. (E)
MEFs infected with either JEV (MOI = 20), DENV (MOI = 20) or ZIKV (MOI = 20) were
treated with ABT-737 (1 μM) or A-1331852 (1 μM) and cell viability was determined at 3
days post-infection. Data are the mean of three independent experiments, represented as the
mean ± SD. Significant differences were determined using Student’s t-test and are indicated by
asterisks (P<0.05) and double asterisks (P<0.01).
(TIF)
S5 Fig. Propagation of JEV in PECs. PECs were infected with JEV (MOI = 5) and infectious
titers were determined by focus-forming assay at 1–4 days post-infection. The data represent
the mean ± SD of two independent experiments.
(TIF)
S6 Fig. Establishment of Bclx+/- mice. (A) Schematic of the establishment of Bclx+/- mice by
the CRISPR/Cas9 system. BDF1-derived zygotes were injected with a px330 vector targeting
the mouse Bclx gene and transplanted into pseudopregnant ICR mice. Newborn F1 mice
were crossed with wild-type BDF1 mice and F2 mice were obtained. DNA sequences sur-
rounding the Bclx gene in F2 mice were confirmed by sequencing. We obtained three Bclx+/-
mouse lines from separate F1 mouse lines (No. 32, No. 40, and No. 44). (B) Spleen lysates
from wild-type or Bclx+/- mice were subjected to immunoblotting using antibodies against
the indicated proteins. (C) Wild-type (n = 9) and Bclx+/- mice (n = 6) mice were subcutane-
ously challenged with JEV (4 x 106 FFU) and footpads were collected at 5 days post-infection.
mRNA levels of Ccl2, Ifna and Ifnb in the footpads were determined by qPCR. (D) Wild-type
(n = 7) and Bclx+/- mice (n = 5) were subcutaneously injected with Poly(I:C) (10 μg) sus-
pended in 50 μL PBS and footpads were collected at 12 h post-inoculation. Expression of
Tnfα and Il6 in the footpads of wild-type and Bclx+/- mice was determined by qPCR. The
relative expression in Bclx+/- mice was represented as the ratio of each value per leg to the
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corresponding value of wild-type mice using the standard curve method. The data represent
each value and mean ± SD.
(TIF)
S1 Table. DNA oligos for generating gene-knockout cell lines.
(PDF)
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